Chinese Antibody Society’s Post

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐓𝐑𝐎𝐏𝐈𝐎𝐍-𝐋𝐮𝐧𝐠𝟎𝟏 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈𝐈 𝐓𝐫𝐢𝐚𝐥 Datopotamab deruxtecan (Dato-DXd) demonstrates promising results in locally advanced or metastatic non-small cell lung cancer (NSCLC). In the overall trial population, Dato-DXd numerically favors OS compared to docetaxel, with statistically significant improvement in PFS, especially in nonsquamous NSCLC. Safety profile of Dato-DXd is consistent with fewer adverse events compared to docetaxel, with no new safety concerns identified. Susan Galbraith, EVP Oncology R&D, AstraZeneca, and Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, express optimism about Dato-DXd potentially replacing conventional chemotherapy in late-line setting. Dato-DXd, a TROP2-directed DXd antibody drug conjugate, is jointly developed by AstraZeneca AstraZeneca and Daiichi Sankyo Daiichi Sankyo. These promising findings will support regulatory applications globally for adult patients with locally advanced or metastatic nonsquamous NSCLC who received prior systemic therapy. #LungCancerResearch #NSCLCtreatment #ClinicalTrialResults #DatoDXd #CancerTreatment #OncologyNews #MedicalBreakthrough #AstraZeneca #DaiichiSankyo

📅 Save the Date: Join LifeSci Events and Cidara Therapeutics for a virtual research and development day on September 21st at 12:00 PM EDT! Reserve your seat: https://lnkd.in/ePs2dP7J 🌟 Featured Speakers: – Jorge Villacian, MD & Penny Heaton, MD from Janssen Pharmaceuticals will present Phase 2a data on CD388 (JNJ-0953), a promising drug candidate aimed at the universal prevention of seasonal flu. – Stephen Schoenberger, PhD of La Jolla Institute for Immunology will shed light on the unmet needs in cancer immunotherapy. – Ezra Cohen, MD, CMO at Tempus, will discuss the emerging significance of drug-Fc conjugates (DFCs) in precision oncology. The leadership team from Cidara will also share exciting updates on its Cloudbreak® pipeline focusing on oncology DFCs, and offer insights into clinical development considerations for DFCs targeting solid tumors. 🎤 Live Q&A: Stay tuned for a live Q&A session where you can get your questions answered by these industry leaders! #InfluenzaPrevention #CancerImmunotherapy #DrugDevelopment #Pharmaceuticals #InfectiousDiseases #Oncology #PrecisionMedicine #LifeSciEvent #LifeSciences

Can EMBARK label expansion rejuvenate Xtandi’s US growth prospects? To provide feedback on the prospects of Pfizer and Astellas Pharma US #Xtandi in #CSPC and how that could affect the treatment algorithm further downstream, we are asking an expert. Learn more here: https://lnkd.in/gX4s-pHW #cancer #clinicalresearch #clinicaltrials #drugdevelopment #oncology #pharmaceuticals #prostatecancer #medicalaffairs

🌟 𝑮𝒊𝒍𝒆𝒂𝒅 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑺𝒍𝒂𝒔𝒉𝒆𝒔 𝑬𝒏𝒕𝒊𝒓𝒆 $4.9𝑩 𝑴𝒂𝒈𝒓𝒐𝒍𝒊𝒎𝒂𝒃 𝑷𝒊𝒑𝒆𝒍𝒊𝒏𝒆 𝑨𝒇𝒕𝒆𝒓 𝑺𝒐𝒍𝒊𝒅 𝑻𝒖𝒎𝒐𝒓 𝑻𝒓𝒊𝒂𝒍𝒔 𝑭𝒂𝒊𝒍 💊 In April 2024, There's a $4.9 billion gap in Gilead Sciences' revenue channels💸. In its first quarter results report, #biotech giant delivered a crushing blow to its anti-CD47 monoclonal antibody magrolimab by eliminating the last of its solid #tumor trials. The antibody has vanished entirely from Gilead's pipeline. #Gilead halted enrollment in all solid tumor trials and terminated development in blood cancers in February. When the FDA requested a partial clinical hold on the trials, Gilead put a stop to the solid tumor trials. However, Gilead was still "evaluating the benefit-risk of 💊magrolimab throughout all ongoing trials" at that point. As part of its Elevate program, Gilead previously tested the antibody in four midphase clinical trials🔬. 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐨𝐮𝐫 𝐂𝐨𝐫𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 👉:https://bit.ly/44l3T8p #GileadScience #MonoclonalAntibody #ClinicalTrials #Magrolimab #OncologyDrugTrials #prophecymarketinsights

The approval of GSK’s OJJAARA (momelotinib) offers renewed hope for patients suffering from myelofibrosis (MF) with anemia, a heterogeneous and rare disease with a poor survival outcome. OJJAARA represents a new arsenal in GSK’s oncology portfolio. With about 45,000 MF patients in the USA and Europe, this approval spells strong commercial opportunity for GSK. #myelofibrosis #cancertherapy #oncology #cancermedicine #development #marketanalysis #marketresearch #marketaccess #pipeline #strategy #intelligence #competitiveintelligence #marketintelligence #eosintelligence #perspectives #leadership #innovation #lifesciences #lifesciencesindustry #biotech #biotechinnovation #biopharma #biopharmaceuticals GSK ---------------------------------------------------------------------------------- Looking to monitor the competitive landscape in the rapidly evolving Oncology treatment landscape, including catalysts, financial metrics, partnerships, pricing and reimbursement? At EOS intelligence, we deliver reliable primary competitive insights that sets the stage for successful product launch and market access Let us know your perspectives & challenges and we will get you covered. Write us at [email protected]

Looks like one of their ADC programs (targeting B7- H3) is moving quickly to P3: "...the study of ifinatamab deruxtecan (I-DXd) is expected to get under way in March to evaluate the B7-H3–targeting ADC in patients with relapsed small-cell lung cancer (SCLC)." Recall that Merck and Daiichi Sankyo, Inc. signed a multi-year alliance on select ADC assets just this past fall. https://lnkd.in/eQCq8M-F #Merck #DaiichiSankyo #ADC #AntibodyDrugConjugates #biotech #Innovation #Pharma #Healthcare #Pipeline #DrugDevelopment #ClinicalStudies #LungCancer #SCLC

HER2-Negative Breast Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AstraZeneca, Laekna, Novartis, Roche, Eli Lilly: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 85 key pharma and biotech companies are working on 85 pipeline drugs in the HER2-Negative Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

https://lnkd.in/d7xt6GgG Key Insights : • BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #BoehringerIngelheim #oxfordtherapeutics #lungcancer #cancer #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

HER2-Negative Breast Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AstraZeneca, Laekna, Novartis, Roche, Eli Lilly: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 85 key pharma and biotech companies are working on 85 pipeline drugs in the HER2-Negative Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

  I am excited to share my upcoming talk at the 19th BioPharma Drug Discovery #Nexus Conference, set to take place in Basel, Switzerland on April 25th.   Join me as we delve into the unique potential of G Protein-Coupled Receptors (#GPCRs) in reshaping the landscape of #cancertreatment through #precisionmedicine.   Despite GPCRs have delivered 30% of currently marketed drugs, their role in cancer treatment remains underexplored. With approximately 56% of GPCRs remaining non-targeted, the potential for GPCRs in immuno-oncology is immense.   At #DomainTherapeutics, one mission drives us all: to #beatresistance and #defeatcancer. Our precision research sheds light to the pivotal role of GPCRs in shaping the #tumormicroenvironment and modulating the #immuneresponse against cancer. Through the meticulous identification and validation of GPCRs implicated in immunosuppression, we're spearheading innovative therapies. Our pipeline boasts a wealth of #clinical and #preclinical fully owned best-in-class and first-in-class therapeutics.   #Joinme as we explore how our precision research is propelling GPCR science forward and bringing in a new era of groundbreaking cancer treatments.   #Immunooncology #PrecisionMedicine #drugdevelopment